Barry Greene, Sage CEO (Adrien Villez for Endpoints News)

Sage fo­cus­es on suc­cess­ful launch of post­par­tum de­pres­sion drug

Sage Ther­a­peu­tics is dou­bling down on the “block­buster po­ten­tial” of its post­par­tum de­pres­sion drug Zurzu­vae, ex­pand­ing pro­fes­sion­al pro­mo­tions and tak­ing steps to­ward a di­rect-to-con­sumer launch …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.